Endostatin - Protgen

Drug Profile

Endostatin - Protgen

Alternative Names: M2ES; Pegylated endostatin

Latest Information Update: 17 Aug 2015

Price : $50

At a glance

  • Originator Protgen
  • Class Angiostatic proteins; Antineoplastics; Recombinant proteins
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Non-small cell lung cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 17 Aug 2015 No recent reports of development identified - Phase-I for Pancreatic cancer (Combination therapy) in China (IV)
  • 17 Aug 2015 No recent reports of development identified - Phase-I for Pancreatic cancer (Second-line therapy or greater) in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top